hefei tnj chemical industry

China Manufacturer of Ruxolitinib C17H18N6 | CAS 941678-49-5

As a leading manufacturer of 941678-49-5 Ruxolitinib (C17H18N6) in China, I understand the critical role quality and reliability play in your purchasing decisions. Our Ruxolitinib is meticulously synthesized, ensuring high purity and efficacy, which are essential for your research and development needs. We pride ourselves on our state-of-the-art production facilities and rigorous quality control processes, so you can trust that our products meet international standards. With competitive pricing and a commitment to timely delivery, I’m confident that partnering with us will enhance your product offerings. You won’t just get a supplier; you’ll gain a reliable partner invested in your success. Let’s work together to streamline your supply chain with the best Ruxolitinib available in the market. Feel free to reach out for more details, pricing, or samples. Your satisfaction is my top priority, and I look forward to helping you achieve your goals.

Hot Selling Product

941678-49-5 Ruxolitinib C17H18N6 Stands Out Dominates

Ruxolitinib, identified by the CAS number 941678-49-5, is rapidly gaining attention in the pharmaceutical market due to its significant role in treating various diseases, particularly myelofibrosis and polycythemia vera. As a Janus kinase (JAK) inhibitor, Ruxolitinib modulates the immune response and has shown promising results in managing disorders linked to abnormal blood cell production. With its unique chemical structure, C17H18N6, it stands out for its efficacy and specificity, making it a preferred choice for healthcare professionals globally. The increasing demand for effective treatments has propelled Ruxolitinib into the spotlight, and suppliers must meet the growing needs of buyers worldwide. Its popularity stems from not only its therapeutic benefits but also its potential for further clinical research, opening avenues for innovative therapies in oncology and immunology. As procurement professionals seek reliable partners for sourcing pharmaceuticals, it becomes essential to focus on quality, compliance, and sustainability in the supply chain. In this dynamic marketplace, staying informed about top-notch ingredients like Ruxolitinib is crucial for making strategic procurement decisions. Companies must prioritize collaborations with manufacturers that adhere to recent regulatory standards and can guarantee the quality of their products. Engaging with suppliers who possess a deep understanding of the global market trends will ensure that buyers acquire the best materials to support their product lines effectively. With the right partnerships, stakeholders can navigate the complexities of the pharmaceutical landscape with confidence.

941678-49-5 Ruxolitinib C17H18N6 Stands Out Dominates

Property Value
Chemical Name Ruxolitinib
CAS Number 941678-49-5
Molecular Formula C17H18N6
Molecular Weight 338.37 g/mol
IUPAC Name N-(1-(2-(pyridin-2-yl)thiazol-4-yl)-1H-imidazol-4-yl)-N'-(pyridin-2-yl)urea
Pharmaceutical Category JAK Inhibitor
Indications Myelofibrosis, Polycythemia Vera
Administration Route Oral
Therapeutic Class Antineoplastic
Side Effects Infection, headache, anemia, diarrhea

Related Products

tnj chemical producer

941678-49-5 Ruxolitinib C17H18N6 Products More Than a Supplier - A Partner

Ruxolitinib Market Trends: Sales Volume by Region (2020-2023)

In recent years, the market for Ruxolitinib has experienced significant shifts across various regions. The chart above illustrates the sales volume of Ruxolitinib (measured in units) from 2020 to 2023 in five major regions: North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa. Notably, North America leads the sales with 4,500 units sold, reflecting the strong demand for Ruxolitinib in treating several inflammatory conditions and cancers. Europe follows with 3,200 units, showcasing its considerable market share. The Asia-Pacific region, while still growing, shows sales of 2,700 units. Latin America and the Middle East & Africa represent smaller markets with 1,500 and 800 units sold respectively. This data indicates not only the regional preferences but also the potential for growth in underserved markets, emphasizing the need for strategic partnerships and targeted marketing efforts in the pharmaceutical landscape.

Top Selling Products